College of Veterinary Medicine, Department of Infectious Diseases, University of Georgia, Athens, GA, USA.
Expert Rev Vaccines. 2023 Jan-Dec;22(1):871-875. doi: 10.1080/14760584.2023.2266033. Epub 2023 Oct 12.
Influenza virus changes its genotype through antigenic drift or shift making it difficult to develop immunity to infection or vaccination. Zoonotic influenza A virus (IAV) strains can become established in humans. Several impediments to human infection and transmission include sialic acid expression, host anti-viral factors (including interferons), and other elements that govern viral replication. Controlling influenza infection, replication, and transmission is important because IAVs cause annual epidemics and occasional pandemics. Effective seasonal influenza vaccines exist, but these vaccines do not fully protect against novel or pandemic strains.
With new vaccine production technology, vaccines can be produced rapidly. Universal IAV vaccines are being developed to protect against seasonal, novel, and zoonotic IAVs. These efforts are being enhanced and accelerated by a better understanding the host immune response to influenza viruses.
This review discusses several implications for future influenza vaccine development. Host immune responses to influenza virus infection or vaccination can guide vaccine development as anti-influenza immunity is affected by responses influenced by the previous immune history including first and subsequent exposures to influenza virus infections and vaccinations.
流感病毒通过抗原漂移或转变改变其基因型,从而难以产生针对感染或疫苗接种的免疫力。 动物源流感 A 病毒 (IAV) 株可在人类中定植。 包括唾液酸表达、宿主抗病毒因子(包括干扰素)和其他控制病毒复制的因素在内的几个因素会阻碍人类感染和传播。 控制流感感染、复制和传播很重要,因为 IAV 每年都会引发流行,偶尔还会引发大流行。 目前已有有效的季节性流感疫苗,但这些疫苗并不能完全预防新型或大流行株。
随着新疫苗生产技术的出现,疫苗可以快速生产。 正在开发通用 IAV 疫苗以预防季节性、新型和动物源 IAV。 通过更好地了解宿主对流感病毒的免疫反应,这些努力正在得到加强和加速。
这篇综述讨论了未来流感疫苗开发的几个意义。 宿主对流感病毒感染或疫苗接种的免疫反应可以指导疫苗开发,因为抗流感免疫受先前免疫史影响,包括首次和随后接触流感病毒感染和接种疫苗。